Send the following on WhatsApp
Continue to Chathttps://forschung.kssg.ch/de/publikationen/9808-efficacy-and-safety-of-dolutegravir-plus-emtricitabine-versus-standard-art-for-the-maintenance-of-hiv-1-suppression-48-week-results-of-the-factorial-randomized-non-inferiority-simplhiv-trial/autoren